Omalizumab Reduces Itch of Severe Chronic UrticariaOmalizumab Reduces Itch of Severe Chronic Urticaria

Swiss drugmaker Novartis said on Saturday its drug omalizumab (Xolair) proved significantly more effective than placebo for patients with a severe form of hives in a late-stage study. Reuters Health Information
Source: Medscape Emergency Medicine Headlines - Category: Emergency Medicine Tags: Dermatology News Source Type: news